Skip to main navigation

Skip to content

News
Careers
Open Positions

About Us
Our Science
Pipeline
Investors

Scientific Publications

Investors

Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Email Alerts
Contact IR
FAQ

Menu

Investors

Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Email Alerts
Contact IR
FAQ

Presentations

Preclinical Evaluation of CFT1946 as a Selective Degrader of Mutant BRAF for the Treatment of BRAF Driven Cancers

Source

AACR Annual Meeting 2022

The Discovery and Characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma

Source

AACR Annual Meeting 2022

The Discovery and Characterization of CFT8634: A Potent and Selective Degrader of BRD9 for the Treatment of SMARCB1-perturbed Cancers

Source

AACR Annual Meeting 2022

AACR Poster Presentation: CFT7455 Phase 1/2 Cohort A

Source

AACR Annual Meeting 2022

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Source

63rd ASH Annual Meeting & Exposition

Discovery of a Potent and Selective BRD9 BiDAC Degrader with Activity in a Preclinical Model of Synovial Sarcoma

Source

4th Annual Targeted Protein Degradation Summit

Discovery of CFT8919 as an oral, CNS-active, mutant-selective allosteric degrader of EGFR L858R for the treatment of EGFR inhibitor resistant non-small cell lung cancer

Source

4th Annual Targeted Protein Degradation Summit

CFT7455: A novel, IKZF1/3 Degrader That Demonstrates Potent Tumor Regression in a Spectrum of Non-Hodgkin Lymphoma Xenograft Models

Source

16th Annual International Conference on Malignant Lymphoma

Preclinical Evaluation of CFT8919 as a Mutant Selective Degrader of EGFR with L858R Activating Mutations for the Treatment of Non-Small Cell Lung Cancer

Source

Keystone Symposium on Targeted Protein Degradation

Lessons Learned in Developing JAK2 Degraders

Source

Keystone Symposium on Targeted Protein Degradation

Pagination

Current page 1
Page 2
Next page
Last page

Scientific Publications

Development of an AchillesTAG degradation system and its application to control CAR-T activity

October 22, 2021

Source

ScienceDirect

Structural Characterization of Degrader-Induced Ternary Complexes Using Hydrogen–Deuterium Exchange Mass Spectrometry and Computational Modeling: Implications for Structure-Based Design

September 28, 2021

Source

ACS Publications

Evaluation of the small-molecule BRD4-degrader CFT-2718 in small cell lung cancer and pancreatic cancer models

May 27, 2021

Source

Molecular Cancer Therapeutics

A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination

March 29, 2021

Source

Sage Journals

High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics

January 11, 2021

Source

Sage Journals

Targeted protein degradation and the enzymology of degraders

June 7, 2018

Source

ScienceDirect

Toolkit

Phone

617-231-0700

Location

490 Arsenal Way, Suite 200 Watertown, MA 02472

Email

info@c4therapeutics.com

© 2022 C4 Therapeutics, Inc.

Privacy Policy Terms of Use Agreement Sitemap

Search for:

About Us
Our Science
Pipeline
Investors
News
Careers
Open Positions

Search for: